Alberto
Carmona Bayonas
Asociado Ciencias de la Salud
![Foto de Alberto](/img/uploaded/c9d7750ad373785985563925a999eee0.jpeg)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (28)
2023
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
-
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
2021
-
Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study
Cancers, Vol. 13, Núm. 18
-
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
Therapeutic Advances in Medical Oncology, Vol. 13
-
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936
-
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)
Health and Quality of Life Outcomes, Vol. 19, Núm. 1
-
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 799-811
2020
-
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750
-
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
PloS one, Vol. 15, Núm. 7, pp. e0235848
2019
-
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544
-
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
Thrombosis and Haemostasis, Vol. 119, Núm. 11, pp. 1849-1859
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
2018
-
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
Gastric Cancer, Vol. 21, Núm. 1, pp. 96-105
-
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study
BMC Cancer, Vol. 18, Núm. 1
-
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
European Journal of Surgical Oncology, Vol. 44, Núm. 8, pp. 1191-1198